Vitamin D for the management of chronic obstructive pulmonary disease

Vitamin D for the management of chronic obstructive pulmonary disease

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. is is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Our primary objectives are to determine whether Vitamin D supplementation reduces the risk of acute exacerbations of chronic obs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane Database of Systematic Reviews 2019-03, Vol.2019 (3), p.i-10
Hauptverfasser: Martineau, A.R, Cates, C.J, Jolliffe, D, Janssens, W, Sheikh, A, Griffiths, C.J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10
container_issue 3
container_start_page i
container_title Cochrane Database of Systematic Reviews
container_volume 2019
creator Martineau, A.R
Cates, C.J
Jolliffe, D
Janssens, W
Sheikh, A
Griffiths, C.J
description Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. is is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Our primary objectives are to determine whether Vitamin D supplementation reduces the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) requiring systemic corticosteroids, antibiotics or both. Our secondary objectives are to evaluate the impact of Vitamin D supplementation on other effectiveness outcomes, including severe AECOPD, i.e. Those requiring emergency department (ED) attendance or hospitalisation, moderate AECOPD, study-defined AECOPD, adverse events, death, symptom control, industrial absenteeism, self-reported short-acting bronchodilator use, quality of life; physiological and biochemical, including lung function, exercise tolerance, muscle strength, biomarkers of inflammation, costeffectiveness and safety in people with COPD.
format Article
fullrecord <record><control><sourceid>kuleuven_FZOIL</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_636947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_636947</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_6369473</originalsourceid><addsrcrecordid>eNqVyjEOwiAUAFAWB6Pe4W8OxkGprZ21xgMYV_Kln5ZYoIFPo7d38QA6veXNRXO3jM56OIMJEbgncOixI0eeIRjQfQzeagiPxDFrthPBmAcXPMY3tDYRJlqKmcEh0errQqwvze103T7zQHkir9o0oia128viUFbHWpWyrItK_jM3v03FL5YflTJErg</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vitamin D for the management of chronic obstructive pulmonary disease</title><source>Lirias (KU Leuven Association)</source><creator>Martineau, A.R ; Cates, C.J ; Jolliffe, D ; Janssens, W ; Sheikh, A ; Griffiths, C.J</creator><creatorcontrib>Martineau, A.R ; Cates, C.J ; Jolliffe, D ; Janssens, W ; Sheikh, A ; Griffiths, C.J</creatorcontrib><description>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. is is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Our primary objectives are to determine whether Vitamin D supplementation reduces the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) requiring systemic corticosteroids, antibiotics or both. Our secondary objectives are to evaluate the impact of Vitamin D supplementation on other effectiveness outcomes, including severe AECOPD, i.e. Those requiring emergency department (ED) attendance or hospitalisation, moderate AECOPD, study-defined AECOPD, adverse events, death, symptom control, industrial absenteeism, self-reported short-acting bronchodilator use, quality of life; physiological and biochemical, including lung function, exercise tolerance, muscle strength, biomarkers of inflammation, costeffectiveness and safety in people with COPD.</description><language>eng</language><ispartof>Cochrane Database of Systematic Reviews, 2019-03, Vol.2019 (3), p.i-10</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,776,27837</link.rule.ids><linktorsrc>$$Uhttps://lirias.kuleuven.be/handle/123456789/636947$$EView_record_in_KU_Leuven_Association$$FView_record_in_$$GKU_Leuven_Association</linktorsrc></links><search><creatorcontrib>Martineau, A.R</creatorcontrib><creatorcontrib>Cates, C.J</creatorcontrib><creatorcontrib>Jolliffe, D</creatorcontrib><creatorcontrib>Janssens, W</creatorcontrib><creatorcontrib>Sheikh, A</creatorcontrib><creatorcontrib>Griffiths, C.J</creatorcontrib><title>Vitamin D for the management of chronic obstructive pulmonary disease</title><title>Cochrane Database of Systematic Reviews</title><description>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. is is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Our primary objectives are to determine whether Vitamin D supplementation reduces the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) requiring systemic corticosteroids, antibiotics or both. Our secondary objectives are to evaluate the impact of Vitamin D supplementation on other effectiveness outcomes, including severe AECOPD, i.e. Those requiring emergency department (ED) attendance or hospitalisation, moderate AECOPD, study-defined AECOPD, adverse events, death, symptom control, industrial absenteeism, self-reported short-acting bronchodilator use, quality of life; physiological and biochemical, including lung function, exercise tolerance, muscle strength, biomarkers of inflammation, costeffectiveness and safety in people with COPD.</description><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVyjEOwiAUAFAWB6Pe4W8OxkGprZ21xgMYV_Kln5ZYoIFPo7d38QA6veXNRXO3jM56OIMJEbgncOixI0eeIRjQfQzeagiPxDFrthPBmAcXPMY3tDYRJlqKmcEh0errQqwvze103T7zQHkir9o0oia128viUFbHWpWyrItK_jM3v03FL5YflTJErg</recordid><startdate>20190325</startdate><enddate>20190325</enddate><creator>Martineau, A.R</creator><creator>Cates, C.J</creator><creator>Jolliffe, D</creator><creator>Janssens, W</creator><creator>Sheikh, A</creator><creator>Griffiths, C.J</creator><scope>FZOIL</scope></search><sort><creationdate>20190325</creationdate><title>Vitamin D for the management of chronic obstructive pulmonary disease</title><author>Martineau, A.R ; Cates, C.J ; Jolliffe, D ; Janssens, W ; Sheikh, A ; Griffiths, C.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_6369473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Martineau, A.R</creatorcontrib><creatorcontrib>Cates, C.J</creatorcontrib><creatorcontrib>Jolliffe, D</creatorcontrib><creatorcontrib>Janssens, W</creatorcontrib><creatorcontrib>Sheikh, A</creatorcontrib><creatorcontrib>Griffiths, C.J</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>Cochrane Database of Systematic Reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Martineau, A.R</au><au>Cates, C.J</au><au>Jolliffe, D</au><au>Janssens, W</au><au>Sheikh, A</au><au>Griffiths, C.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D for the management of chronic obstructive pulmonary disease</atitle><jtitle>Cochrane Database of Systematic Reviews</jtitle><date>2019-03-25</date><risdate>2019</risdate><volume>2019</volume><issue>3</issue><spage>i</spage><epage>10</epage><pages>i-10</pages><abstract>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd. is is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Our primary objectives are to determine whether Vitamin D supplementation reduces the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) requiring systemic corticosteroids, antibiotics or both. Our secondary objectives are to evaluate the impact of Vitamin D supplementation on other effectiveness outcomes, including severe AECOPD, i.e. Those requiring emergency department (ED) attendance or hospitalisation, moderate AECOPD, study-defined AECOPD, adverse events, death, symptom control, industrial absenteeism, self-reported short-acting bronchodilator use, quality of life; physiological and biochemical, including lung function, exercise tolerance, muscle strength, biomarkers of inflammation, costeffectiveness and safety in people with COPD.</abstract></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof Cochrane Database of Systematic Reviews, 2019-03, Vol.2019 (3), p.i-10
issn
language eng
recordid cdi_kuleuven_dspace_123456789_636947
source Lirias (KU Leuven Association)
title Vitamin D for the management of chronic obstructive pulmonary disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A46%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven_FZOIL&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20for%20the%20management%20of%20chronic%20obstructive%20pulmonary%20disease&rft.jtitle=Cochrane%20Database%20of%20Systematic%20Reviews&rft.au=Martineau,%20A.R&rft.date=2019-03-25&rft.volume=2019&rft.issue=3&rft.spage=i&rft.epage=10&rft.pages=i-10&rft_id=info:doi/&rft_dat=%3Ckuleuven_FZOIL%3E123456789_636947%3C/kuleuven_FZOIL%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true